Tag: ETR

Finance

Investors Watch List : Merck & Co (NYSE:MRK), Activision Blizzard (NASDAQ:ATVI), Brooks Automation (NASDAQ:BRKS), Entergy Corporation (NYSE:ETR), CytRx Corporation (NASDAQ:CYTR)

Merck & Co. Inc. (NYSE:MRK) has been sued by Bristol-Myers Squibb Co (BMY) and Ono Pharmaceutical Co., Ltd. (Japan) (OPHLY) for patent infringement of Bristol-Myers’ novel PD-1 inhibitor, Optivo. Merck recently won the US Food and Drug Administration’s (FDA) approval for its own PD-1 drug, Keytruda. This made the company the first one to enter the US immunotherapy market, which is expected to reach $35 … Continue reading Investors Watch List : Merck & Co (NYSE:MRK), Activision Blizzard (NASDAQ:ATVI), Brooks Automation (NASDAQ:BRKS), Entergy Corporation (NYSE:ETR), CytRx Corporation (NASDAQ:CYTR)

Chris Lewis
Finance

NSYE Overbought Stocks: Exelon Corporation (NYSE:EXC), Goodrich Petroleum Corporation (NYSE:GDP), Entergy Corporation (NYSE:ETR), Aspen Insurance Holdings (NYSE:AHL)

Exelon Corporation (NYSE:EXC)’s stock had its “outperform” rating reaffirmed by analysts at Credit Suisse in a research report issued to clients and investors on Tuesday. Exelon Corporation (NYSE:EXC) stock performance was 2.01% in last session and finished the day at $36.00. Traded volume was 7.26million shares in the last session and the average volume of the stock remained 7.45million shares. The beta of the stock … Continue reading NSYE Overbought Stocks: Exelon Corporation (NYSE:EXC), Goodrich Petroleum Corporation (NYSE:GDP), Entergy Corporation (NYSE:ETR), Aspen Insurance Holdings (NYSE:AHL)

Colin Pettis
Finance

Why Trader’s Are Watching: Curis, Inc. (NASDAQ:CRIS), BlackBerry Ltd (NASDAQ:BBRY), Goldfield Corp. (NYSEMKT:GV), Entergy Corporation (NYSE:ETR), Las Vegas Sands Corp. (NYSE:LVS)

On Dec. 18, Curis, Inc. (NASDAQ:CRIS) announced that the first patient has initiated treatment with CUDC-907 in a Phase 1 clinical trial in patients with advanced or relapsed solid tumors, including hormone receptor positive (HR+)/ HER2-negative breast cancer or midline carcinoma with certain NUT gene rearrangements. CUDC-907 is an oral, dual inhibitor of histone deacetylase (HDAC) and phosphoinositide 3-kinase (PI3K) enzymes that is currently under … Continue reading Why Trader’s Are Watching: Curis, Inc. (NASDAQ:CRIS), BlackBerry Ltd (NASDAQ:BBRY), Goldfield Corp. (NYSEMKT:GV), Entergy Corporation (NYSE:ETR), Las Vegas Sands Corp. (NYSE:LVS)

Kristen Barton